Skip to main content

David Martinez Selva

Institutions of which they are part

Main researcher
Diabetes and Metabolism
Vall Hebron Institut de Recerca

David Martinez Selva

Institutions of which they are part

Main researcher
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Projects

Diabetis i Metabolisme (GRC)

IP: Rafael Simó Canonge
Collaborators: Josep A Villena Delgado, Carles Zafon Llopis, Cristina Hernández Pascual, David Martinez Selva, Andreea Ciudin Mihai, Lorena Ramos Pérez, Rosa Burgos Peláez, Olga Simó Servat, Patricia Bogdanov Baruj
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 40000
Reference: 2014 SGR 270
Duration: 01/01/2014 - 31/12/2016

Pendent de complimentar

IP: Rafael Simó Canonge
Collaborators: David Martinez Selva, Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 101250
Reference: CPII14/00032
Duration: 01/02/2015 - 31/01/2018

Mecanismos moleculares que regulan la expresión de la SHBG en la obesidad y en la distribución de la grasa corporal inducida por la dieta: implicaciones terapéuticas

IP: David Martinez Selva
Collaborators: M Luisa Chicharro Serrano, Andreea Ciudin Mihai, Lorena Ramos Pérez
Funding agency: Instituto de Salud Carlos III
Funding: 183315
Reference: PI12/01357
Duration: 01/01/2013 - 31/12/2015

Papel de la Sex Hormone-Binding Globulin (SHBG) y de los esteroides sexuales en la distribución de la grasa corporal en la aparición de la diabetes mellitus tipo 2

IP: David Martinez Selva
Collaborators: Lorena Ramos Pérez
Funding agency: Instituto de Salud Carlos III
Funding: 81070
Reference: PI09/00144
Duration: 01/01/2010 - 31/12/2012

Related news

Funding has been obtained for 43 projects under the calls for Health R&D&I Projects, Health Technology Development, and Independent Clinical Research

The work represents a paradigm shift in the clinical approach to this chronic, multifactorial disease, based on the clinical context of each patient and not only on weight loss.

The results of a phase 3 clinical trial show that orforglipron reduces body weight by an average of 11% and improves cardiovascular risk factors.

Related professionals

Kerrie Adrián Campbell

Kerrie Adrián Campbell

Research technician
Neurovascular Diseases
Read more
Novica Nikolic

Novica Nikolic

Research assistant
Clinical Research/Innovation in Pneumonia & Sepsis (CRIPS)
Read more
Laia Yañez Bisbe

Laia Yañez Bisbe

Postdoctoral researcher
Cardiovascular Diseases
Read more
Bernat Serra Creus

Bernat Serra Creus

Predoctoral researcher
Cardiovascular Diseases
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.